This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.
RSA 126-Z:5 · Severability
126-Z:5 Severability. – If any provision of this chapter, or the application thereof to any person or circumstance is held invalid, the invalidity does not affect the other provisions or applications of the chapter which can be given effect without the invalid provisions or applications and to this end the provisions of this chapter are severable. Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025.
Copy linkSource note
Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025.
Source history
- 2016, 206:2, eff. June 6, 2016
- 2024, 124:1, eff. Jan. 1, 2025
Related materials
Bill relationships
-
2026 HB1292
amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
-
2026 HB1292-FN
amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
-
2026 HB1809
reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
-
2026 HB1809-FN
reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
-
2026 SB504
reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
-
2026 SB504-FN
reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
-
2026 SB616
amend · effective 2027-07-01
r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to
-
2026 SB616-FN
amend · effective 2027-07-01
r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to